QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Brian Helfand; MD, PhD presenting at the recent American Urological Association meeting. At present, while PSA is the best diagnostic tool for early diagnosis of prostate cancer, it is not perfect for cancer detection. Benign conditions also can cause an…
New studies* on PSA Velocity (PSAV) suggest that PSAV risk count, the number of times PSAV exceeds a specific threshold, could increase the reliability of screening for prostate cancer and of screening potentially for life-threatening tumors. PSA Velocity is the…
Previous studies have established median* PSA values for men in their 40s, 50s, 60s and 70s. These are 0.7, 0.9, 1.3, and 1.7 ng/mL, respectively. Prior studies have also demonstrated that men who have PSA values above their age-specific median…
Prostate cancer is among the most genetically influenced cancers. Out of the millions of possible SNPs that exist in the human genome; so far, approximately 40 have been associated with prostate cancer risk, and this study looked at 36 of…
On May 21, 2012, the *American Urological Association (AUA) released the following statement in response to the U.S. Preventive Services Task Force (USPSTF) recommendation on the use of the prostate-specific antigen (PSA) test. The statement is attributed to AUA President…
Physicians want new treatments to work, especially for patients who no longer respond to existing treatments. Physicians want new treatments to work, especially for patients who no longer respond to existing treatments. It was controversial from the get go because…
Phi is the pro-PSA divided by the free-PSA times the square root of the total PSA. “Phi has fewer false positives than existing tests and is more specific for aggressive prostate cancer,” Dr. Catalona said. Dr. Catalona launched the implementation…
Expanded Access to MDV3100 Access to MDV3100 has been expanded to clinical studies in 10 states. QUEST reported on MDV3100 in its Spring 2011 issue: MDV3100 represents a major advance in the hormonal treatment of patients with apparent castration-resistant prostate…
Negligible PSA PSA after removal of the prostate should be negligible because no prostate cells should remain. Depending somewhat on how high the PSA level was before surgery, the PSA should be less than 0.1 in the first follow-up visit…
PSA testing is a topic of conversation and controversy in the media because of the recent USPSTF (U.S. Preventive Services Task Force) recommendation against PSA screening. The recommendation for PSA testing by the American Urological Association and its 18,000 urologist…
"*" indicates required fields
